-
公开(公告)号:EP4387603A1
公开(公告)日:2024-06-26
申请号:EP22859207.7
申请日:2022-08-19
发明人: WANG, Guoqiang , MA, Jun , GRANGER, Brett , LONG, Jiang , WANG, Bin , GHORAI, Sourav , HE, Jing , HE, Yong , XING, Xuechao , SHEN, Ruichao , OR, Yat, Sun
IPC分类号: A61K31/18 , A61K31/63 , C07C311/08
CPC分类号: C07C311/21 , C07C307/10 , C07C2601/0820170501 , C07C2601/1420170501 , C07C2602/1020170501 , C07C2601/1620170501 , C07D277/36 , C07D217/08 , C07D215/58 , C07D265/36 , C07D471/04 , C07D209/08 , C07D209/44 , C07D277/22 , C07D231/12 , C07D417/04 , C07D417/12 , C07D231/18 , C07D263/46 , C07D209/30 , C07D307/79 , C07D333/62 , C07D307/82 , C07D333/34 , C07D417/14 , C07D417/10 , C07D277/54 , A61P1/00
-
2.SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 有权
标题翻译: 具有酰胺基的磺胺衍生物和药物可接受的盐公开(公告)号:EP2740723B1
公开(公告)日:2017-05-10
申请号:EP12763010.1
申请日:2012-03-30
发明人: KIM, Ki Young , AHN, Jin Hee , KANG, Seung Kyu , BAE, Myung Ae , AHN, Sung Hoon , KIM, Hee Youn , JUNG, Won Hoon , KANG, Nam Sook , RHEE, Sang Dal
IPC分类号: C07C307/10 , A61K31/18 , A61P3/10
CPC分类号: C07D417/04 , A61K31/18 , C07C307/10 , C07C2603/74 , C07D285/10 , C07D285/14 , C07D285/15 , C07D285/16 , C07D285/36 , C07D417/10 , C07D417/12
-
公开(公告)号:EP3046902A4
公开(公告)日:2017-01-25
申请号:EP14845828
申请日:2014-09-17
发明人: DUGGAN KAREN ANNETTE
IPC分类号: C07C235/34 , A61K31/165 , A61K31/17 , A61K31/18 , C07C233/07 , C07C233/11 , C07C237/20 , C07C255/00 , C07C271/28 , C07C275/28 , C07C307/10 , C07C311/03 , C07D209/18 , C07D213/74 , C07D215/02 , C07D231/56 , C07D235/04 , C07D249/18 , C07D263/54 , C07D277/62
CPC分类号: C07D263/58 , C07C235/34 , C07C237/20 , C07C255/61 , C07C261/04 , C07C271/28 , C07C275/42 , C07C307/10 , C07C311/03 , C07C311/08 , C07D209/08 , C07D209/18 , C07D209/34 , C07D213/74 , C07D213/89 , C07D215/02 , C07D215/227 , C07D231/56 , C07D235/04 , C07D235/08 , C07D235/10 , C07D235/26 , C07D249/18 , C07D263/54 , C07D277/62 , C07D277/68
摘要: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
-
公开(公告)号:EP2674417A3
公开(公告)日:2014-04-09
申请号:EP13000717.2
申请日:2008-11-20
申请人: Decode Genetics EHF
发明人: Singh, Jasbir , Gurney, Mark , Burgin, Alex , Sandanayaka, Vincent , Kiselyov, Alexander , Motta, Adalie , Schultz, Gary , Hategan, Georgeta , Hagen, Timothy
IPC分类号: C07D207/16 , C07D213/64 , C07D213/79 , C07D231/12 , C07D239/42 , C07D401/06 , C07D471/04 , C07D473/18 , C07D473/40 , C07D285/135 , C07D213/06 , C07D213/74 , C07D213/75 , C07D213/84 , C07D401/04 , C07D233/90 , C07D275/06 , C07D213/89 , C07D403/04 , A61P9/10 , A61K31/4439
CPC分类号: C07C217/84 , A61K31/136 , A61K31/397 , A61K31/41 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/4418 , A61K31/4427 , A61K31/5377 , A61K45/06 , C07B2200/05 , C07C65/40 , C07C69/94 , C07C275/32 , C07C275/62 , C07C305/24 , C07C307/10 , C07D205/04 , C07D207/16 , C07D213/38 , C07D213/40 , C07D213/64 , C07D213/65 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/84 , C07D213/89 , C07D231/12 , C07D233/90 , C07D239/42 , C07D257/04 , C07D275/06 , C07D277/42 , C07D285/12 , C07D285/135 , C07D401/04 , C07D401/06 , C07D403/04 , C07D471/04 , C07D473/18 , C07D473/40
摘要: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I:
-
5.Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders 审中-公开
标题翻译: 联芳基PDE4抑制剂对肺癌和心血管疾病的治疗公开(公告)号:EP2628727A3
公开(公告)日:2013-12-25
申请号:EP13000709.9
申请日:2008-11-20
申请人: Decode Genetics EHF
发明人: Singh, Jasbir , Gurney, Mark , Burgin, Alex , Kiselyov, Alexander , Rao, Munagala , Hagen, Timothy
IPC分类号: C07D207/16 , C07D213/64 , C07D213/79 , C07D231/12 , C07D239/42 , C07D401/06 , C07D471/04 , C07D473/18 , C07D473/40 , C07D285/135 , C07D213/06 , C07D213/74 , C07D213/75 , C07D213/84 , C07D401/04 , C07D233/90 , C07D275/06 , C07D213/89 , C07D403/04 , A61P9/10 , A61K31/4439
CPC分类号: C07C217/84 , A61K31/136 , A61K31/397 , A61K31/41 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/4418 , A61K31/4427 , A61K31/5377 , A61K45/06 , C07B2200/05 , C07C65/40 , C07C69/94 , C07C275/32 , C07C275/62 , C07C305/24 , C07C307/10 , C07D205/04 , C07D207/16 , C07D213/38 , C07D213/40 , C07D213/64 , C07D213/65 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/84 , C07D213/89 , C07D231/12 , C07D233/90 , C07D239/42 , C07D257/04 , C07D275/06 , C07D277/42 , C07D285/12 , C07D285/135 , C07D401/04 , C07D401/06 , C07D403/04 , C07D471/04 , C07D473/18 , C07D473/40
摘要: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id:
or salt thereof, in particular a pharmaceutically acceptable salt thereof.-
公开(公告)号:EP2533775A1
公开(公告)日:2012-12-19
申请号:EP11704214.3
申请日:2011-02-14
发明人: EBBESEN, Peter , SUPURAN, Claudiu T. , SCOZZAFAVA, Andrea , PETTERSEN, Erik Olai , WILLIAMS, Kaye , DUBOIS, Ludwig , LAMBIN, Philippe
IPC分类号: A61K31/18 , A61P35/00 , C07C311/00
CPC分类号: A61K49/0021 , C07C307/02 , C07C307/10 , C07C335/18 , C07C2601/14
摘要: A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R-NH-CX-NH-(CH
2 )
n -Ar-Q-SO
2 -NH
2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n = 0, 1 or 2; Q is O or NH; X is O or S; and R comprises an organic substituent group.摘要翻译: 包含通式R-NH-CX-NH-(CH 2)n -Ar-Q-SO 2 -NH 2的化合物或其药学上可接受的盐,衍生物或前体药物的碳酸酐酶IX(CA IX)抑制剂 物; 其中n = 0,1或2; Q是O或NH; X是O或S; 并且R包含有机取代基。
-
公开(公告)号:EP2491015A1
公开(公告)日:2012-08-29
申请号:EP10763138.4
申请日:2010-10-07
IPC分类号: C07C307/10 , C07C311/08 , C07C311/14 , A61K31/18 , A61P35/00
CPC分类号: C07C311/14 , C07C307/10 , C07C311/08 , C07C2601/02 , C07C2601/04
摘要: The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及通式(I)的取代苯并磺酰胺化合物:其中R 1,R 2,R 3,R 4,R 5和A如权利要求中所定义,涉及制备所述化合物的方法,药物组合物和包含所述化合物 并涉及所述化合物用于制造用于治疗或预防疾病,特别是过度增殖和/或血管生成失调的药物组合物作为唯一药剂或与其他活性成分组合的用途。
-
8.Use of beta 3 adrenergic receptor agonists in the treatment of dysuria 有权
标题翻译: Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie公开(公告)号:EP1382333B1
公开(公告)日:2009-02-25
申请号:EP03021612.1
申请日:1999-03-25
申请人: Astellas Pharma Inc.
发明人: Taniguchi, Kiyoshi , Sakurai, Minoru , Fujii, Naoaki , Hosoi, Kumi , Tomishima, Yasuyo , Takasugi, Hisashi , Sogabe, Hajime , Ishikawa, Hirofumi , Hanioka, Naomi
IPC分类号: A61K31/165 , A61K31/223 , A61K31/404 , A61K31/4045 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4468 , A61K31/495 , A61K31/501 , A61K31/5375 , A61P13/02
CPC分类号: C07D213/40 , A61K31/165 , A61K31/223 , A61K31/404 , A61K31/4045 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4468 , A61K31/495 , A61K31/501 , A61K31/5375 , C07C215/46 , C07C217/30 , C07C217/74 , C07C219/24 , C07C229/18 , C07C229/50 , C07C233/25 , C07C233/43 , C07C233/80 , C07C235/20 , C07C235/24 , C07C237/48 , C07C271/24 , C07C271/30 , C07C271/58 , C07C275/22 , C07C279/22 , C07C307/02 , C07C307/10 , C07C311/08 , C07C311/18 , C07C317/32 , C07C323/25 , C07C323/41 , C07C2601/06 , C07C2601/14 , C07C2602/12 , C07D209/08 , C07D209/16 , C07D211/26 , C07D213/73 , C07D213/85 , C07D233/60 , C07D235/26 , C07D277/46 , C07D295/185 , C07D401/04 , C07D417/14
-
公开(公告)号:EP1477472B1
公开(公告)日:2009-01-14
申请号:EP03706983.8
申请日:2003-02-20
发明人: SHODA, Motoshi , KURIYAMA, Hiroshi
IPC分类号: C07C69/734 , C07C59/62 , C07C59/68 , C07C229/42 , C07C205/56 , C07C233/54 , C07C235/06 , C07C235/16 , C07C235/20 , C07C237/20 , C07C275/42 , C07D209/18 , C07D215/14 , C07D215/22 , C07D231/56 , C07D307/68 , C07D307/79 , C07D277/64 , C07D277/82 , C07D333/60 , C07D409/12 , A61K31/19 , A61K31/215 , A61K31/405 , A61K31/425 , A61K31/41 , A61P25/04 , A61P37/00
CPC分类号: C07C59/58 , C07C59/68 , C07C59/72 , C07C69/734 , C07C229/42 , C07C307/10 , C07C2601/08 , C07D209/08 , C07D209/18
摘要: A compound represented by the general formula (I):[wherein n is an integer of 1 to 3; R represents C3-8 alkyl, a group represented by R1(CH2)k- (k is an integer of 0 to 3; and R1 represents C3-7 saturated cycloalkyl or C6-8 fused-ring saturated alkyl, provided that R1 may be substituted by C1-4 alkyl), etc.; and Ar represents a bicyclic fused-ring group, e.g., naphthalen-1-yl] or a salt of the compound. The compound or salt has prostaglandin and leukotriene production inhibitory activity. It is useful for the prevention of and treatments for, e.g., various inflammatory diseases attributable to the lipid mediator.
-
10.METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS 有权
标题翻译: METHOD FOR疾病与丙二酰辅酶A脱羧酶抑制剂于治疗公开(公告)号:EP1353662B1
公开(公告)日:2007-04-18
申请号:EP02703196.2
申请日:2002-01-22
发明人: ARRHENIUS, Thomas Chugai Biopharmaceuticals, Inc. , CHEN, Mi Chugai Biopharmaceuticals, Inc. , CHENG, Jie Fei Chugai Biopharmaceuticals, Inc. , HARAMURA, Masayuki Chugai Biopharmaceuticals, Inc. , HUANG, Yujin Chugai Biopharmaceuticals, Inc. , NADZAN, Alex Chugai Biopharmaceuticals, Inc. , TITH, Sovouthy Chugai Biopharmaceuticals, Inc. , WALLACE, David Chugai Biopharmaceuticals, Inc. , ZHANG, Lin Chugai Biopharmaceuticals, Inc. , BROWN, Steve Chugai Biopharmaceuticals, Inc. , HARMON, Charles Chugai Biopharmaceuticals, Inc. , LOPASCHUK, Gary , DYCK, Jason
IPC分类号: A61K31/16 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/44 , A61K31/42 , A61K31/5375 , A61P3/04 , A61P3/10 , A61P9/10 , A61P35/00
CPC分类号: C07D231/06 , A61K31/16 , A61K31/165 , A61K31/17 , A61K31/175 , A61K31/18 , A61K31/197 , A61K31/221 , A61K31/275 , A61K31/40 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/4178 , A61K31/4188 , A61K31/4196 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4439 , A61K31/451 , A61K31/5375 , A61K31/5377 , C07C33/46 , C07C33/48 , C07C215/24 , C07C233/22 , C07C257/22 , C07C279/18 , C07C307/10 , C07C323/14 , C07C335/18 , C07D231/14 , C07D233/64 , C07D233/90 , C07D239/42 , C07D261/04 , C07D261/08 , C07D261/14 , C07D261/18 , C07D277/46 , C07D277/48 , C07D277/52 , C07D285/135 , C07D295/13 , C07D295/194 , C07D295/21 , C07D295/215 , C07D295/32 , C07D307/46 , C07D307/52 , C07D401/12 , C07D413/06 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/08 , C07F9/247 , C07F9/4021 , C07F9/6539
摘要: The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds.
-
-
-
-
-
-
-
-
-